A Randomized, Double-blind, Placebo-controlled, Cross-over, Single-dose Study to Evaluate the Effects of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia Including a One Week Multiple-dose Extension to Assess the Persistence of Observed Effects and a Multiple-dose Cross Over Study in Non Smokers Only.
Phase of Trial: Phase II
Latest Information Update: 19 Apr 2012
At a glance
- Drugs AQW 051 (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 19 Apr 2012 Last checked against ClinicalTrials.gov record.
- 19 Apr 2012 Actual patient number 57 added as reported by ClinicalTrials.gov.
- 19 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.